IP Library Granted Patent US 7,951,544
Granted Patent B1
US 7,951,544 · App. 10/030,497 · Granted May 31, 2011

Method for determining the prognosis of cancer patients by measuring levels of bag expression

Assignee: Sanford-Burnham Medical Research Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,951,544
App. No.
10/030,497
Granted
May 31, 2011
Kind
B1
Abstract

In accordance with the present invention, there are provided methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. Also provided are methods for predicting the risk of tumor recurrence or spread in an individual having a cancer tumor. Methods for screening a cancer patient to determine the risk of tumor metastasis; methods for determining the proper course of treatment for a patient suffering from cancer; and kits for use in practising the invention methods.

Claims (19)

1. A method for determining the risk of tumor recurrence or spread in a patient suffering from prostate cancer, said method comprising:

(a) determining a cytosolic BAG-1 protein level in a cancerous prostate tissue sample from said patient; and

(b) comparing said cytosolic BAG-1 protein level in said sample to a reference cytosolic BAG-1 protein level, said reference level being a level of cytosolic BAG-1 protein above which correlates with an increased risk of tumor recurrence or spread and below which correlates with a decreased risk of tumor recurrence or spread, thereby determining the risk of tumor recurrence or spread in said patient.

2. The method of claim 1 , wherein said tumor spread comprises tumor metastasis.

3. The method of claim 1 , wherein said cytosolic BAG-1 protein level is determined with an antibody specific for BAG-1 protein.

4. The method of claim 1 , wherein said cytosolic BAG-1 protein comprises BAG-1N and BAG-1M.

5. The method of claim 1 , wherein said cytosolic BAG-1 protein level is determined using an immunoassay.

6. The method of claim 5 , wherein said immunoassay is an immuno-polymerase chain reaction (immuno-PCR) assay.

7. The method of claim 1 , wherein said reference cytosolic BAG-1 protein level is a level of cytosolic BAG-1 protein above which correlates with increased risk of tumor recurrence or spread in a first group of patients compared to a second group of patients, said second group of patients having cytosolic BAG-1 protein levels below said reference level.

8. A method for determining a prognosis of survival in a patient suffering from prostate cancer, said method comprising:

(a) determining a cytosolic BAG-1 protein level in a cancerous prostate tissue sample from said patient; and

(b) comparing said cytosolic BAG-1 protein level in said sample to a reference cytosolic BAG-1 protein level, said reference level being a level of cytosolic BAG-1 protein above which correlates with decreased survival and below which correlates with increased survival, thereby determining a prognosis of survival in said patient.

9. The method of claim 8 , wherein said survival is overall survival.

10. The method of claim 8 , wherein said survival is distant metastasis-free survival.

11. The method of claim 8 , wherein said cytosolic BAG-1 protein level is determined with an antibody specific for BAG-1 protein.

12. The method of claim 8 , wherein said cytosolic BAG-1 protein comprises BAG-1N and BAG-1M.

13. The method of claim 8 , wherein said cytosolic BAG-1 protein level is determined using an immunoassay.

14. The method of claim 13 , wherein said immunoassay is an immuno-polymerase chain reaction (immuno-PCR) assay.

15. The method of claim 8 , wherein said reference cytosolic BAG-1 protein level is a level of cytosolic BAG-1 protein above which correlates with decreased survival in a first group of patients compared to a second group of patients, said second group of patients having cytosolic BAG-1 protein levels below said reference level.

Assignments (5)
CHANGE OF NAME Recorded Feb 11, 2011
From: THE BURNHAM INSTITUTE
To: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 025795/0298 →
CHANGE OF NAME Recorded Feb 11, 2011
From: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 025799/0902 →
CONFIRMATORY LICENSE Recorded Jun 5, 2008
From: THE BURNHAM INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021052/0590 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRESPONDENCE ADDRESS, PREVIOUSLY RECORDED ON REEL 013122 FRAME 0694 Recorded Oct 15, 2002
From: REED, JOHN C.
To: BURNHAM INSTITUTE, THE
Reel/Frame 013382/0758 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2002
From: REED, JOHN C.
To: BURNHAM INSTITUTE, THE
Reel/Frame 013122/0694 →
Continuity (1)
Continuation 09350518 · Jul 9, 1999